Join Us


Read More


Read More

Our Policy

Read More

Contact Us

Read More

About Us

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. Xynomic Pharma focus on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Partnerships with MNCs including Pharmacyclics/AbbVie, Boehringer Ingelheim and Janssen.

Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin’s lymphoma (as a single agent). Abexinostat has granted 2 Fast-Track designations from FDA. Xynomic’s XP-105 (BI 860585) is a Phase 2 ready, ATP-competitive mTORC1/2 inhibitor against solid tumors. Xynomic’s XP-102 (BI 882370) is a Phase 1 ready pan-RAF inhibitor.

Xynomic Pharma founded by experienced multinational veterans and successful entrepreneurs. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies.

Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and rest of the world. Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner.

Xynomic Pharma is headquartered in the Shanghai with major operations in US and Shanghai, China.

Latest News

See More Posts